GermanVasc@CA_Behrendt retweetledi

🔍 Focused update - ESVS PAD Guidelines
Recently published high-quality evidence, particularly the SWEDEPAD 2 trial, showed no meaningful quality-of-life benefit and raised concerns about possible long-term mortality with paclitaxel-coated devices, challenging prior assumptions about their net benefit. This prompted a focused update given the potential direct impact on patient safety and clinical decision-making in patients with intermittent claudication
Read the article here: ejves.com/article/S1078-…
@robhinchliffe1 @AWanhainen @VASCevidence

English



































